Brief: Reata Pharmaceuticals Announces Outcome Of FDA Advisory Committee Meeting Of Bardoxolone
08/12/2021 23:25
Dec 8 (Reuters) - Reata Pharmaceuticals Inc RETA.O :
* REATA PHARMACEUTICALS ANNOUNCES OUTCOME OF FDA ADVISORY
COMMITTEE MEETING OF BARDOXOLONE FOR THE TREATMENT OF PATIENTS
WITH CHRONIC KIDNEY DISEASE CAUSED BY ALPORT SYNDROME
* REATA - COMMITTEE VOTED NO ON QUESTION OF WHETHER PROVIDED
EVIDENCE DEMONSTRATED THAT BARDOXOLONE IS EFFECTIVE IN SLOWING
PROGRESSION OF CKD
Source text for Eikon: ID:nBw3cGHBva
Further company coverage: RETA.O
Recent news on Reata Pharmaceuticals
See all newsReata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Biogen Inc Says If Deal Terminated Under Certain Conditions, Reata Will Be Required To Pay Biogen Termination Fee Equal To $264 Mln
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
Biogen’s $7 bln deal goes smaller and safer